baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out GILD/ DE000UK8SD90 /

9/20/2024 9:51:13 PM	Chg.+0.03	Bid10:00:19 PM	Ask10:00:19 PM	Underlying	Strike price	Expiration date	Option type
3.93EUR	+0.77%	- Bid Size: -	- Ask Size: -	Gilead Sciences Inc	126.4789 USD	12/31/2078	Put

GlobeNewswire 8/27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

GlobeNewswire 8/8 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 8/8 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire 8/8 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire 8/6 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

GlobeNewswire 8/5 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 8/5 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

GlobeNewswire 8/1 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire 7/23 ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...

GlobeNewswire 7/15 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...

GlobeNewswire 7/8 Memo Therapeutics AG appoints Paul Carter as Chairperson

GlobeNewswire 7/4 Burns McClellan Mourns the Passing of Founder and CEO, Lisa Burns

GlobeNewswire 7/1 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...

GlobeNewswire 7/1 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...

GlobeNewswire 6/28 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 6/26 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

GlobeNewswire 6/26 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors

TeleTrader 6/20 US opens mostly higher after labor, housing data

GlobeNewswire 6/18 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 6/17 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 6/10 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 5/22 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 5/14 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

UBS Knock-Out GILD/ DE000UK8SD90 /

If you wish to receive reply to your feedback, please provide your email address.